Elicio Therapeutics Announced That Preliminary Analysis Of Patients In The Ongoing Phase 2 AMPLIFY-7P Trial Indicated That Specific Human Leukocyte Antigen Types; ELI-002 7P Shows Broad T-Cell Response Against mKRAS-Mutated Cancers Across Diverse Patient HLA Types

Author: Benzinga Newsdesk | October 27, 2025 08:22am

• ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient population
• Patients treated with ELI-002 7P represented a diverse HLA repertoire including 1,132 unique types identified among 1,398 total HLA backgrounds in assessed patients
• 99% (88/89) of patients assessed for HLA background induced mKRAS-specific T cell responses after treatment with ELI-002 7P
• Induction of mKRAS-specific T cell responses suggest that ELI-002 7P may address a broad patient population with high unmet need for pancreatic ductal adenocarcinoma ("PDAC")

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that preliminary analysis of patients in the ongoing Phase 2 AMPLIFY-7P trial indicated that specific Human Leukocyte Antigen ("HLA") types (alleles) were not associated with a patient's ability to elicit robust mKRAS-specific T-cell response following treatment with ELI-002 7P. 

Among 89 patients treated with ELI-002 7P, a total of 1,132 unique HLAs were represented across the primary class I and class II variants, highlighting substantial genetic diversity within the study population. These findings are consistent with a growing body of evidence indicating that mKRAS antigens can be presented across a broad range of HLA types. Elicio's data is consistent with recent analysis published in Cell Reports Methods that found T cells specific to mKRAS G12D and/or G12V in 20/20 (100%) healthy donors evaluated across a diverse HLA background, suggesting that the majority of patients possess mKRAS-presenting HLAs and include mKRAS-specific T cell responses within their immune repertoire.

Posted In: ELTX